Under a tenth of individuals eligible to benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it issues its inaugural guidance on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for more widespread and fairer access to GLP-1 medication.
Based on estimates, over two billion could be living with obesity by 2030 if no action is taken.
"The latest guidelines recognises that excess weight is a long-term condition that can be addressed with thorough and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are key hurdles to broad availability to the treatments that can aid individuals in losing significant weight, explains the body.
Skinny Jab Supply Crisis
Despite the present most optimistic scenario, the supply of these medications could only cover about 100 million people – fewer than 10% of those who need them, as stated by the WHO.
The guideline encourages governments and firms to widen availability, by approaches such as patent sharing.
The intellectual property rights on semaglutide – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026.
The Way Obesity Drugs Work
These medications imitate a biological compound to delay gastric emptying, curb appetite and enhance the sense of being full so people eat less.
Individuals commonly see weight reduction within a few weeks of starting on the weekly injections.
Research points to people may put most of the weight back on after a year of discontinuing the treatment, as their normal appetite resume.
To be overweight or obese elevates your likelihood for experiencing health problems, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, as per the health agency.
